Healthcare / BiotechnologyTaipei Exchange
$52.30
-0.70 (-1.30%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-48.3M · quality 79.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.5B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-4.8%
↓Gross Margin
16.7%
↓Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-13.2%
FCF CAGR
—
FCF margin
-10.5%
FCF / Net income
0.74x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $346.1M · net income $-49.6M · FCF $-36.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $346.1M | $346.1M | $467.8M | $440.5M | $529.1M |
| Net Income | $-49.6M | $-49.6M | $-48.5M | $-55.0M | $-74.2M |
| EBITDA | $-39.5M | $-39.5M | $-34.7M | $-41.7M | $-55.4M |
| EPS | — | — | -1.49 | -1.69 | -2.28 |
| Gross Margin | 16.7% | 16.7% | 17.3% | 16.2% | 15.6% |
| Operating Margin | -16.9% | -16.9% | -13.2% | -14.6% | -15.5% |
| Net Margin | -14.3% | -14.3% | -10.4% | -12.5% | -14.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.03 | 0.03 | 0.03 |
| Current Ratio | 11.77 | 11.77 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-36.5M | $-36.5M | $-48.3M | $-71.4M | $-54.0M |
| Returns | |||||
| ROE | -4.8% | -4.8% | -11.9% | -10.7% | -16.8% |
| Valuation | |||||
| P/B | 3.39 | 3.39 | 2.44 | 3.08 | 2.88 |
| Growth & Yield | |||||
| Revenue Growth | -26.0% | -26.0% | 6.2% | -16.7% | — |
| EPS Growth | — | — | 11.8% | 25.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+62.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.49 → n/d
Residual
+62.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.